Hirudin: Physiology and What Research Reports

What hirudin is

Hirudin is a small, single-chain polypeptide — about 65 amino acids in most described forms — that was originally isolated from the salivary secretions of medicinal leeches. Its defining property is direct, highly selective inhibition of thrombin, the serine protease that cleaves fibrinogen into fibrin during clot formation. A 2021 review in Frontiers in Pharmacology summarised hirudin and its derivatives as direct thrombin inhibitors and catalogued reported pharmacological activities extending beyond anticoagulation, including effects described in fibrosis, kidney injury and tumour models (PMID 33935784).

Unlike heparin, which works indirectly through antithrombin, hirudin was described in that same review as acting on thrombin itself, which is why it is often used in the literature as a reference tool compound for studying thrombin-dependent biology (PMID 33935784). This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis, treatment or medication.

Where it is produced

Hirudin is not a human peptide. It is a product of leech salivary gland tissue, where it forms part of a secretion that keeps host blood liquid during feeding. Researchers examining European medicinal leeches reported that the hirudin gene family is larger than classically assumed, characterising additional "hirudin-like factors" designated HLF3 and HLF4 as previously hidden members of that family (PMID 32363441). That work is relevant to peptide science because it shows the sequence space around hirudin is broader than the single canonical molecule.

Material used in modern research is generally recombinant rather than leech-extracted. A 2022 Biomaterials Advances study, for example, used recombinant hirudin as the grafted molecule when the researchers functionalised surfaces to achieve both anticoagulation and reduced non-specific protein adsorption (PMID 35929214).

What it does in the body

Because thrombin sits at the centre of the coagulation cascade, inhibiting it affects more than fibrin formation. Thrombin also signals through cell-surface receptors on endothelial cells, podocytes, fibroblasts and immune cells, and much of the non-coagulation literature on hirudin is built on that idea. The 2021 review grouped the reported activities of hirudin and its derivatives into anticoagulant/antithrombotic actions plus additional effects described in renal, fibrotic and oncological models (PMID 33935784).

How hirudin is measured and studied

As a laboratory anticoagulant

Hirudin has a niche role in analytical laboratories. A paper in the Journal of Automated Methods & Management in Chemistry reported that hirudin could serve as a blood-collection anticoagulant suitable for both haematology and clinical chemistry testing, in contrast to anticoagulants that bind cations and interfere with chemistry assays (PMID 18924865).

In biomaterials and delivery engineering

Two engineering-oriented papers illustrate how hirudin is used as a functional building block rather than a systemic agent. In the surface-functionalisation study, researchers reported that recombinant hirudin modification conferred anticoagulant character and anti-non-specific-adsorption behaviour on the treated surface (PMID 35929214). In Science Advances, a separate group described a self-regulated hirudin delivery system for anticoagulant therapy, in which release was designed to respond to coagulation activity rather than proceed at a fixed rate (PMID 33036973).

In animal and cell models

Most recent hirudin papers are preclinical: rodent disease models, cultured glomerular endothelial cells or podocytes, tumour cell lines, and parasite cultures. Readings of these papers should keep in mind that the models differ widely and that no human outcome trial appears in the set summarised here.

What the literature reports

Kidney models

Kidney research is the largest cluster. A 2024 Biomedicine & Pharmacotherapy study reported that hirudin delayed progression in a diabetic kidney disease model and linked this to inhibition of glomerular endothelial cell migration and abnormal angiogenesis (PMID 39178812). A later FASEB Journal paper reported that hirudin ameliorated kidney injury in diabetic kidney disease mice, with the researchers attributing the effect to decreased SOD2 β-hydroxybutyrylation, lower reactive oxygen species levels and reduced NLRP3 inflammasome formation (PMID 41546551).

In a podocyte-injury model, researchers reported that hirudin attenuated puromycin aminonucleoside-induced glomerular podocyte injury and that the effect involved inhibition of MAPK-mediated endoplasmic reticulum stress (PMID 35277865).

Fibrosis models

A transcriptome-based network analysis in unilateral ureteral obstruction (UUO) rats reported that hirudin potentiated anti-renal-fibrosis efficacy in that model (PMID 34621173). A 2025 paper in Acta Cirúrgica Brasileira reported that hirudin inhibited ferroptosis and improved renal fibrosis, which the study attributed to targeting of the STAT3/NLRP3 signalling pathway (PMID 40298655).

Tumour and parasite models

Outside the kidney, a 2023 study in the Journal of Cellular and Molecular Medicine reported that hirudin inhibited glioma growth through mTOR-regulated autophagy (PMID 37539490). Separately, a drug-design paper reported in-vitro antileishmanial potential for hirudin as a peptide drug candidate (PMID 27483399).

Safety and adverse events: what studies report

The papers summarised here were mechanistic and model-based, and none was designed as a human safety trial; they did not report adverse-event rates in people. The engineering literature nonetheless reflects a practical concern with controlling exposure: the Science Advances group built a self-regulated delivery platform precisely so that hirudin release would track coagulation activity rather than being administered at a fixed, unresponsive rate (PMID 33036973). The 2021 review, which surveyed hirudin and its derivatives across indications, remains the most complete published overview of its pharmacology and mechanisms (PMID 33935784). Questions about anticoagulant risk in a specific person belong with a treating clinician, not with a literature summary.

Why the term appears in peptide reading

Hirudin is often the first example given of a naturally occurring peptide protease inhibitor with a well-defined molecular target, which is why it appears in teaching material on peptide pharmacology, in coagulation chapters, and in biomaterial-coating literature. Readers encountering "hirudin peptide" in a research context are usually meeting either the recombinant molecule used as a laboratory reagent or a derivative studied in one of the preclinical models above.

Limits of the evidence

• Most recent findings come from rodent and cell models, not human trials.
• Mechanisms reported — NLRP3, STAT3, MAPK, mTOR — were inferred within single studies and have not been cross-validated across models in this literature set.
• Hirudin is a non-human peptide, so species and formulation differences matter when interpreting results.

References

• Pharmacological Activities and Mechanisms of Hirudin and Its Derivatives - A Review (Frontiers in Pharmacology, 2021)
• The hirudin-like factors HLF3 and HLF4 - hidden hirudins of European medicinal leeches (Parasitology Research, 2020)
• Surface functionalization of anticoagulation and anti-nonspecific adsorption with recombinant hirudin modification (Biomaterials Advances, 2022)
• Self-regulated hirudin delivery for anticoagulant therapy (Science Advances, 2020)
• Hirudin as an anticoagulant for both haematology and chemistry tests (Journal of Automated Methods & Management in Chemistry, 2000)
• Hirudin delays the progression of diabetic kidney disease by inhibiting glomerular endothelial cell migration and abnormal angiogenesis (Biomedicine & Pharmacotherapy, 2024)
• Hirudin Ameliorates Kidney Injury in DKD Mice by Decreasing SOD2 β-Hydroxybutyrylation Mediated ROS Level and NLRP3 Inflammasome Formation (FASEB Journal, 2026)
• Transcriptome-Based Network Analysis Reveals Hirudin Potentiates Anti-Renal Fibrosis Efficacy in UUO Rats (Frontiers in Pharmacology, 2021)
• Hirudin inhibits ferroptosis to improve renal fibrosis by targeting the STAT3/NLRP3 signaling pathway (Acta Cirurgica Brasileira, 2025)
• Hirudin attenuates puromycin aminonucleoside-induced glomerular podocyte injury by inhibiting MAPK-mediated endoplasmic reticulum stress (Drug Development Research, 2022)
• Hirudin inhibits glioma growth through mTOR-regulated autophagy (Journal of Cellular and Molecular Medicine, 2023)
• In-vitro antileishmanial potential of peptide drug hirudin (Chemical Biology & Drug Design, 2017)